Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, University of Sydney, discusses the RADICAL trial of patients with melanoma.

The phase III multicenter RADICAL trial is investigating patients with lentigo maligna melanoma. Lengito maligna is an early stage of melanoma that is generally found in elderly patients and is difficult to operate on.

In the trial, patients were randomized to radiotherapy or imiquimod to determine the efficacy of these treatments. The primary endpoint is treatment failure at 6 months that is biopsy proven. Secondary endpoints include treatment failure at 12 months and 24 months.

Videos

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.

Pascale Guitera, MD

Articles

Dr. Guitera on the RADICAL Trial for Melanoma